UNSPSC 51172302: Digoxin Immune Fab

This classification denotes an antitdote for digitalis overdose with the molecular formula C6394H9908N1698O2011S58, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YB12NQZ1YN.

UNSPSC 51172302 Digoxin Immune Fab is a Commodity code for a specific pharmaceutical product — an antitoxin used to treat digoxin toxicity — yet recent state and local solicitations tagged with this code show little procurement activity directly aligned with the product itself. Instead, the opportunities reflect broader pharmaceutical procurement, drug testing services, and pharmacy benefit program management that fall outside the scope of this narrow specialty pharmaceutical. State and local governments soliciting under this code include county supervision and corrections departments managing offender drug-testing programs, state health and human services agencies developing pharmacy benefit initiatives, and multistate cooperative purchasing alliances coordinating pharmaceutical supply across participating jurisdictions.

The geographic spread includes Texas (Collin County Community Supervision and Corrections Department, Texas Health and Human Services Commission) and Minnesota (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Representative recent opportunities are the Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026, estimated contract value of $600,000 over two years with three optional one-year renewals; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026, to establish multiple contracts effective July 1, 2026. The mismatch between the code's narrow pharmaceutical scope and the diverse procurement activities tagged to it suggests this code may see limited direct activity for digoxin immune fab itself and is better used as a signal of broader state and local pharmacy and pharmaceutical services procurement rather than a reliable tracker of specialty antitoxin demand.